ALERTS, HOT STOCKS & CHARTS

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Redefining Gut Health With Plexus Armor Here we go, folks—a big leap in digestive health with Plexus Worldwide unveiling Plexus Armor. If you've ever found yourself wading through a maze of gut supplements, this might just raise your flag. It's like they're saying, "We’ve had enough of digestive discomfort," and aiming to tackle it head-on. Plexus isn't new to this...

G Mining Ventures Releases NI 43-101 Technical Report G Mining Ventures Corporation is excited to announce the completion and filing of a new technical report in accordance with National Instrument 43-101. This report pertains to the Oko West Gold Project located in Guyana, underscoring the company's commitment to maintaining transparent operations and providing...

Strong Financial Performance in Q4 2024 Shell plc has reported impressive financial results for the fourth quarter of 2024, showcasing resilience amid challenges. The company generated a robust free cash flow of $40 billion for the entire year, surpassing the previous year's results despite a fluctuating market environment. This accomplishment reflects Shell's steadfast...

PureHealth Research Unveils New Ashwagandha Supplement As research highlights a significant connection between chronic stress and adverse health effects, including cognitive decline, PureHealth Research is stepping forward with a groundbreaking solution. The company has recently launched its doctor-approved Ashwagandha supplement, targeted at individuals grappling with...

Advocating for Non-Market Housing Solutions The Federal Housing Advocate is urging the government to prioritize non-market housing in addressing the ongoing housing crisis. This pivotal move aims to ensure that federal housing policies fulfill the nation's human rights commitments, emphasizing that actions must be taken quickly to reverse the alarming trends in housing...